Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

1.9K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.9K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

602
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
602
Other Disorders of Digestive System01:30

Other Disorders of Digestive System

1.7K
The gastrointestinal tract is susceptible to various disorders. If the lower esophageal sphincter is damaged, stomach acid can flow back into the esophagus, causing irritation and inflammation of the lining. This condition is called gastroesophageal reflux disease (known as heartburn) and may cause chest pain and difficulty swallowing. In the stomach, prolonged use of nonsteroidal anti-inflammatory drugs like aspirin, chronic alcohol consumption, bacterial infections such as Helicobacter...
1.7K
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

1.7K
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
1.7K
Esophageal Strictures-I: Introduction01:30

Esophageal Strictures-I: Introduction

1.1K
Esophageal strictures involve abnormal narrowing or tightening of the esophagus. They vary in length and severity, ranging from mild constriction to complete obstruction, and are classified as benign (noncancerous) or malignant (cancerous).
Etiology
The primary cause of esophageal strictures is long-standing gastroesophageal reflux disease (GERD), accounting for about 70 to 80% of adult cases. Chronic acid reflux can lead to injury and scarring of the esophageal lining, culminating in...
1.1K
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

1.6K
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adverse effects and duration of treatment of TB in Canterbury, New Zealand.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2021
Same author

The complement receptor 3 (CD11b/CD18) agonist Leukadherin-1 suppresses human innate inflammatory signalling.

Clinical and experimental immunology·2016
Same author

The heritability and genetics of complement C3 expression in UK SLE families.

Genes and immunity·2009
Same author

Pulmonary hypertension complicating sarcoidosis.

Internal medicine journal·2008
Same author

The genetics of SLE: an update in the light of genome-wide association studies.

Rheumatology (Oxford, England)·2008
Same author

Quantification of the genetic component of basal C-reactive protein expression in SLE nuclear families.

Annals of human genetics·2008

Related Experiment Video

Updated: Mar 21, 2026

Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices
04:09

Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices

Published on: June 13, 2025

1.5K

NON-CELIAC SPRUE: A CASE OF OLMESARTAN-INDUCED ENTEROPATHY.

W Penn1, B Rhodes1, Z Bruce1

  • 1Department of Internal Medicine, LSU Health Sciences Center, Baton Rouge, Louisiana.

The Journal of the Louisiana State Medical Society : Official Organ of the Louisiana State Medical Society
|May 10, 2016
PubMed
Summary

Celiac sprue, marked by diarrhea and weight loss, is typically diagnosed via antibody tests. When these tests are negative, other conditions like infections or neoplasms must be explored for villous atrophy.

More Related Videos

Multimodality Diagnosis of Mesenteric Ischemia
05:07

Multimodality Diagnosis of Mesenteric Ischemia

Published on: July 21, 2023

1.4K
Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices
02:14

Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices

Published on: August 1, 2025

2.0K

Related Experiment Videos

Last Updated: Mar 21, 2026

Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices
04:09

Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices

Published on: June 13, 2025

1.5K
Multimodality Diagnosis of Mesenteric Ischemia
05:07

Multimodality Diagnosis of Mesenteric Ischemia

Published on: July 21, 2023

1.4K
Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices
02:14

Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices

Published on: August 1, 2025

2.0K

Area of Science:

  • Gastroenterology
  • Immunology
  • Pathology

Background:

  • Villous atrophy, a key feature of celiac sprue, often presents with diarrhea and weight loss.
  • Diagnosis of celiac sprue typically relies on serological markers such as tissue transglutaminase (tTG) and endomysial antibodies.

Purpose of the Study:

  • To highlight the differential diagnosis of villous atrophy in patients with negative celiac disease serologies.
  • To emphasize the importance of considering alternative etiologies when initial diagnostic tests are inconclusive.

Main Methods:

  • Review of clinical presentations associated with villous atrophy.
  • Analysis of diagnostic challenges in cases with negative celiac serology.

Main Results:

  • Negative serological tests for celiac sprue necessitate further investigation.
  • Differential diagnoses for villous atrophy include infections, irritable bowel disease, intestinal neoplasms, and drug-induced enteropathy.

Conclusions:

  • Villous atrophy can result from conditions other than celiac sprue.
  • A comprehensive diagnostic approach is crucial for patients presenting with villous atrophy and negative celiac disease antibodies.